NO20091734L - Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse - Google Patents

Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse

Info

Publication number
NO20091734L
NO20091734L NO20091734A NO20091734A NO20091734L NO 20091734 L NO20091734 L NO 20091734L NO 20091734 A NO20091734 A NO 20091734A NO 20091734 A NO20091734 A NO 20091734A NO 20091734 L NO20091734 L NO 20091734L
Authority
NO
Norway
Prior art keywords
compounds
receptor antagonist
methods
glucagon receptor
preparations containing
Prior art date
Application number
NO20091734A
Other languages
English (en)
Other versions
NO342172B1 (no
Inventor
Emma R Parmee
James R Tata
John E Stelmach
Keith G Rosauer
Ronald M Kim
Amy R Bittner
Jiang Chang
Christopher Joseph Sinz
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38982644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091734(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20091734L publication Critical patent/NO20091734L/no
Publication of NO342172B1 publication Critical patent/NO342172B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Glukagonreseptorantagonistforbind- elser beskrives. Forbindelsene er anvendbare for behandling av type 2 diabetes og beslektede tilstander. Farmasøytiske preparater og behandlingsfremgangsmåter omfattes også. (I)
NO20091734A 2006-10-03 2009-04-30 Glukagonreseptorantagonistforbindelser eller farmasøytisk aksepterbare salter derav, farmasøytisk sammensetning derav, og anvendelse derav ved behandling av type 2 type 2 diabetes mellitus eller hyperglykemi, diabetes eller insulinresistens i en pattedyrpasient NO342172B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896706P 2006-10-03 2006-10-03
PCT/US2007/020858 WO2008042223A1 (en) 2006-10-03 2007-09-27 Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Publications (2)

Publication Number Publication Date
NO20091734L true NO20091734L (no) 2009-06-04
NO342172B1 NO342172B1 (no) 2018-04-09

Family

ID=38982644

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091734A NO342172B1 (no) 2006-10-03 2009-04-30 Glukagonreseptorantagonistforbindelser eller farmasøytisk aksepterbare salter derav, farmasøytisk sammensetning derav, og anvendelse derav ved behandling av type 2 type 2 diabetes mellitus eller hyperglykemi, diabetes eller insulinresistens i en pattedyrpasient

Country Status (30)

Country Link
US (3) US20100004158A1 (no)
EP (1) EP2079688B1 (no)
JP (1) JP2010505828A (no)
KR (1) KR20090076907A (no)
CN (1) CN101535252A (no)
AR (1) AR063022A1 (no)
AU (1) AU2007305430B2 (no)
BR (1) BRPI0717305A2 (no)
CA (1) CA2664004C (no)
CL (1) CL2007002841A1 (no)
CO (1) CO6190512A2 (no)
CR (1) CR10694A (no)
DK (1) DK2079688T3 (no)
EA (1) EA017800B1 (no)
EC (1) ECSP099225A (no)
ES (1) ES2390296T3 (no)
GE (1) GEP20125506B (no)
IL (1) IL197788A0 (no)
MA (1) MA31963B1 (no)
MX (1) MX2009003611A (no)
NO (1) NO342172B1 (no)
PE (1) PE20080676A1 (no)
PL (1) PL2079688T3 (no)
PT (1) PT2079688E (no)
SI (1) SI2079688T1 (no)
TN (1) TN2009000111A1 (no)
TW (1) TW200821284A (no)
UA (1) UA96308C2 (no)
WO (1) WO2008042223A1 (no)
ZA (1) ZA200901694B (no)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体
CA2645639A1 (en) * 2006-03-23 2007-10-04 Merck & Co. Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7935713B2 (en) * 2006-05-16 2011-05-03 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) * 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
MX2009008534A (es) 2007-02-09 2009-11-23 Metabasis Therapeutics Inc Antagonistas novedosos del receptor de glucagon.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GEP20135844B (en) 2008-03-05 2013-06-10 Takeda Pharmaceutical Heterocyclic compound
US8623818B2 (en) 2008-05-16 2014-01-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonists, compositions, and methods for their use
PT2799428T (pt) 2008-08-13 2017-02-17 Metabasis Therapeutics Inc Antagonistas de glicagina
WO2010030722A1 (en) * 2008-09-15 2010-03-18 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8361959B2 (en) * 2008-10-03 2013-01-29 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
US8445538B2 (en) * 2008-12-19 2013-05-21 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds
WO2010080971A1 (en) 2009-01-12 2010-07-15 Merck Sharp & Dohme Corp. Crystalline polymorphic forms of an antidiabetic compound
US20110281795A1 (en) * 2009-01-28 2011-11-17 Songnian Lin Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010093535A1 (en) * 2009-02-12 2010-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8809579B2 (en) 2009-02-13 2014-08-19 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2010098994A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011037815A1 (en) 2009-09-22 2011-03-31 Schering Corporation Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
EA023517B1 (ru) 2011-02-08 2016-06-30 Пфайзер Инк. Модуляторы глюкагонового рецептора
US8927577B2 (en) * 2011-07-22 2015-01-06 Pfizer Inc. Quinolinyl glucagon receptor modulators
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
WO2015066252A1 (en) * 2013-11-04 2015-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
US10076504B2 (en) 2014-06-12 2018-09-18 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN107304180B (zh) * 2016-04-22 2022-04-29 浙江海正药业股份有限公司 苯甲酰胺类衍生物、其制备方法及其在医药上的用途
CN109071420B (zh) * 2016-06-14 2021-06-18 上海昂睿医药技术有限公司 酰胺类衍生物、其制备方法及其在医药上的用途
CN107759522B (zh) * 2016-08-15 2023-04-14 浙江海正药业股份有限公司 羧酸类衍生物、其制备方法及其在医药上的用途
MX2019002437A (es) 2016-08-30 2019-10-09 Regeneron Pharma Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.
EP3529278A1 (en) 2016-10-20 2019-08-28 Regeneron Pharmaceuticals, Inc. Methods of lowering blood glucose levels
US20210130480A1 (en) 2017-08-22 2021-05-06 Regeneron Pharmaceuticals, Inc. Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
WO2019160940A1 (en) 2018-02-13 2019-08-22 Ligand Pharmaceuticals Incorporated Glucagon receptor antagonists
CN112608378B (zh) * 2020-12-09 2023-09-08 江苏师范大学 一类glp-1/胆囊收缩素-1受体双重激动剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU702887B2 (en) 1995-10-31 1999-03-11 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
WO1998021957A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles, compositions containing such compounds and methods of use
CA2271941A1 (en) 1996-11-20 1998-05-28 Merck & Co., Inc. Triaryl substituted imidazoles and methods of use
JP2000514088A (ja) 1996-11-20 2000-10-24 メルク エンド カンパニー インコーポレーテッド グルカゴンアンタゴニストとしてのトリアリール置換イミダゾール
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
JP2003514508A (ja) 1997-07-01 2003-04-15 ノボ ノルディスク アクティーゼルスカブ グルカゴン拮抗剤／逆作用剤
HUP0101099A3 (en) 1997-12-19 2002-09-30 Amgen Inc Thousand Oaks Substituted pyridine and pyridazine compounds and their pharmaceutical use
HUP0201033A3 (en) 1999-05-17 2003-03-28 Novo Nordisk As Glucagon antagonists/inverse agonists, process for their preparation and their use
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
JP2004501897A (ja) 2000-06-23 2004-01-22 ノボ　ノルディスク　アクティーゼルスカブ グルカゴン拮抗薬／逆作用薬
US20030203946A1 (en) 2000-11-17 2003-10-30 Carsten Behrens Glucagon antagonists/inverse agonists
AU2002223501A1 (en) 2000-11-17 2002-05-27 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
MXPA03009000A (es) * 2001-04-13 2004-02-12 Boehringer Ingelheim Pharma Compuestos benzo-fusionados 1,4-disustituidos.
EP1430024A1 (en) * 2001-09-18 2004-06-23 F. Hoffmann-La Roche Ag Alkyl urea retinoid agonists i
AU2002365622A1 (en) 2001-12-03 2003-06-17 Novo Nordisk A/S Novel glucagon antagonists
WO2003051357A1 (en) 2001-12-19 2003-06-26 Novo Nordisk A/S Glucagon receptor antagonists/inverse agonists
WO2003053938A1 (en) 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
JP4415216B2 (ja) 2002-02-01 2010-02-17 大日本住友製薬株式会社 ２−フランカルボン酸ヒドラジド化合物及びそれを含有する医薬組成物
EP1519723A1 (en) 2002-06-27 2005-04-06 Novo Nordisk A/S Novel glucagon antagonists/inverse agonists
PT1537078E (pt) * 2002-08-29 2010-06-18 Merck Sharp & Dohme Indoles que possuem actividade antidiabética
WO2006102067A1 (en) * 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Also Published As

Publication number Publication date
PL2079688T3 (pl) 2013-01-31
ECSP099225A (es) 2009-07-31
EP2079688B1 (en) 2012-07-25
CL2007002841A1 (es) 2008-02-08
KR20090076907A (ko) 2009-07-13
SI2079688T1 (sl) 2012-12-31
PE20080676A1 (es) 2008-06-12
CO6190512A2 (es) 2010-08-19
US7687534B2 (en) 2010-03-30
UA96308C2 (ru) 2011-10-25
CA2664004A1 (en) 2008-04-10
CN101535252A (zh) 2009-09-16
BRPI0717305A2 (pt) 2014-03-25
PT2079688E (pt) 2012-11-22
AR063022A1 (es) 2008-12-23
WO2008042223A1 (en) 2008-04-10
MA31963B1 (fr) 2011-01-03
EP2079688A1 (en) 2009-07-22
IL197788A0 (en) 2009-12-24
US20100144824A1 (en) 2010-06-10
ES2390296T3 (es) 2012-11-08
EA200970342A1 (ru) 2009-10-30
AU2007305430A1 (en) 2008-04-10
NO342172B1 (no) 2018-04-09
US20080085926A1 (en) 2008-04-10
ZA200901694B (en) 2010-01-27
TW200821284A (en) 2008-05-16
AU2007305430B2 (en) 2011-07-21
CA2664004C (en) 2013-07-23
JP2010505828A (ja) 2010-02-25
US7968589B2 (en) 2011-06-28
DK2079688T3 (da) 2012-11-05
CR10694A (es) 2009-05-25
US20100004158A1 (en) 2010-01-07
GEP20125506B (en) 2012-04-25
EA017800B1 (ru) 2013-03-29
MX2009003611A (es) 2009-04-22
TN2009000111A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
WO2007111864A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
NO20070073L (no) Pyrazolderivater, preparater inneholdende disse og metoder for anvendelse derav
ATE449604T1 (de) Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
DK2026803T3 (da) Sammensætninger af R(+) og S(-) pramipexol og fremgangsmåder til anvendelse heraf
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
DK1901731T3 (da) Niacinreceptoragonister, sammensætninger indeholdende sådanne forbindelser og fremgangsmåder til behandling
DE602006019825D1 (de) 1-substituierte-7-(b-d-glycopyranosyloxy)(aza)indolverbindung und pharmazeutikum, das diese enthält
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
NO20084380L (no) Neuromedin U-reseptoragonister og anvendelser derav
DK1523488T3 (da) Nye thiophenglycosidderivater, fremgangsmåder til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20080010L (no) GPCR-agonister
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
UA87991C2 (en) Substituted indole-o-glucosides
ATE459620T1 (de) Benzimidazolthiophenverbindungen als plk- modulatoren
DK1939204T3 (da) Kondenseret heterocyklisk derivat, medicinalsammensætning indeholdende samme og medicinsk anvendelse deraf
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
TW200745044A (en) Pyrazole derivatives, compositions containing such compounds and methods of use
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
ATE466841T1 (de) 1-phenethylpiperidinderivate und ihre verwendung als opioidrezeptor-liganden
EA200700949A1 (ru) Фармацевтические композиции, основанные на антагонистах nk2, для применения в педиатрической практике

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees